NEXUS Epigenomics AB

The human genome, sequenced and catalogued at enormous expense over the past three decades, has turned out to be only part of the biological story. The genome encodes the instructions for building every protein in the body, but which genes are active in which cells, at which stages of development, and in response to which environmental signals — these questions are answered not by the genome itself but by the epigenome: the rich and dynamic layer of chemical modifications and structural features that regulate gene expression without changing the underlying DNA sequence. Understanding the epigenome is increasingly recognised as essential to understanding development, ageing, and the molecular basis of disease. NEXUS Epigenomics AB is a Swedish company dedicated to making that understanding achievable. The company has built a versatile analytical platform for profiling multiple layers of the epigenome simultaneously — an approach that is scientifically important because different epigenetic marks contribute distinct and complementary information. DNA methylation patterns, histone modification landscapes, chromatin accessibility profiles, and three-dimensional genome organisation each reveal aspects of gene regulation that the others do not. A platform capable of capturing multiple layers in a single integrated workflow dramatically increases the richness, resolution, and interpretability of the epigenomic data that researchers can generate. Whole-genome-scale profiling is a defining technical characteristic of NEXUS's tools. This scale matters because the epigenomic changes associated with complex diseases — cancer, neurological conditions, metabolic disorders, immunological diseases — are distributed across the entire genome in patterns that cannot be understood from targeted sequencing of selected loci. Only genome-wide data provides the complete picture that meaningful discovery and biomarker development require. The platform is designed to be innovative and accessible — lowering the technical and financial barriers to high-quality epigenomic profiling while maintaining the scientific rigour that research, clinical development, and regulatory applications demand. NEXUS Epigenomics builds a versatile solution that goes beyond the genome, offering its users proprietary tools for DNA profiling across the entire genome — innovative, tested, and designed for the research environments where the most important epigenomic questions are being asked. The company's growth strategy is built on partnerships and ecosystem development, working with academic research groups, pharmaceutical and biotechnology companies, and clinical research organisations who need epigenomic profiling capabilities as integral components of their discovery and development workflows. The stated ambition is to be the technology partner of choice for the next generation of researchers determined to go beyond the genome and unlock what epigenomics can reveal about health and disease.